https://www.tiaft2023.org/biochip-array-technology-for-new-psychoactive-substances-detection-in-biological-samples/2022-06-30T09:07:55+00:00https://www.tiaft2023.org/addictedchem-a-data-driven-integrated-platform-for-new-psychoactive-substance-identification/2023-05-31T10:22:10+00:00https://www.tiaft2023.org/a-new-strategy-for-efficient-retrospective-data-analyses-for-designer-benzodiazepines-in-large-lc-hrms-datasets/2023-04-03T10:41:37+00:00https://www.tiaft2023.org/epigenetic-studies-for-evaluation-of-nps-toxicity/2022-06-30T09:22:02+00:00https://www.tiaft2023.org/identification-of-the-synthetic-cannabinoid-type-new-psychoactive-substance-ch-piaca-in-seized-material/2023-04-03T10:41:28+00:00https://www.tiaft2023.org/characterization-of-new-psychoactive-substances-by-integrating-benchtop-nmr-to-multi-technique-databases/2022-06-30T09:26:27+00:00https://www.tiaft2023.org/pharmacological-affinity-fingerprints-derived-from-bioactivity-data-for-the-identification-of-designer-drugs/2022-06-30T09:27:53+00:00https://www.tiaft2023.org/establishment-of-neurotoxicity-assessment-using-microelectrode-array-mea-with-hipsc-derived-neurons-and-evaluation-of-new-psychoactive-substances-nps/2023-04-03T10:41:53+00:00https://www.tiaft2023.org/a-simplified-strategy-to-assess-the-cytotoxicity-of-new-psychoactive-substances-in-hepg2-cells-using-a-high-content-screening-assay/2023-04-03T10:42:13+00:00https://www.tiaft2023.org/portable-near-infrared-spectroscopy-for-the-isomeric-differentiation-of-new-psychoactive-substances/2022-09-29T09:47:59+00:00https://www.tiaft2023.org/clinical-features-associated-with-adb-butinaca-exposure-in-patients-attending-emergency-departments-in-england/2023-04-03T10:42:33+00:00https://www.tiaft2023.org/canberra-ketamine-new-recreational-drug-discovered-at-australian-pill-testing-service/2022-12-19T09:59:54+00:00https://www.tiaft2023.org/development-and-validation-of-a-gc-ms-ei-method-to-determine-%ce%b1-php-in-blood-application-to-samples-collected-during-medico-legal-autopsies/2023-05-31T10:21:58+00:00https://www.tiaft2023.org/synthesis-of-emerging-cathinones-and-validation-of-a-spe-gc-ms-method-for-their-simultaneous-quantification-in-blood/2022-12-19T10:29:07+00:00https://www.tiaft2023.org/molecular-insights-and-clinical-outcomes-of-drugs-of-abuse-adulteration-new-trends-and-new-psychoactive-substances-2/2023-05-31T10:21:20+00:00https://www.tiaft2023.org/hexahydrocannabinol-pharmacology-toxicology-and-analysis-the-first-evidence-for-a-recent-new-psychoactive-substance/2023-08-03T10:14:23+00:00https://www.tiaft2023.org/psychotic-like-experiences-and-concurrent-substance-use-among-people-who-use-new-psychoactive-substances/2023-08-03T10:08:12+00:00https://www.tiaft2023.org/a-qualitative-study-investigating-self-medication-with-novel-psychoactive-substances-nps/2023-08-03T10:12:01+00:00https://www.tiaft2023.org/comprehensive-testing-and-rapid-dissemination-of-local-drug-supply-surveillance-data-in-rhode-island/2024-03-06T10:38:23+00:00https://www.tiaft2023.org/monitoring-for-fentanyl-within-australian-supervised-injecting-facilities-findings-from-feasibility-testing-of-novel-methods-and-collaborative-workshops/2023-08-03T10:17:31+00:00https://www.tiaft2023.org/the-dilemma-of-new-psychoactive-substances-a-growing-threat/2023-08-03T10:19:22+00:00